Literature DB >> 16426843

Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner.

Hadas Dvory-Sobol1, Efrat Cohen-Noyman, Diana Kazanov, Arie Figer, Shlomo Birkenfeld, Liora Madar-Shapiro, Robert Benamouzig, Nadir Arber.   

Abstract

A unique in vitro system has been developed in our lab that consists of normal enterocytes derived from the rat ileum (IEC-18 cells) and their transformed derivatives with c-K-ras (R1 cells), anti-sense bak (B3 cells) and cyclin D1 (D1 cells). R1 and B3 cells express high level of COX-2 protein and PGE2. IEC 18 and D1 cells express negligible amount of COX-2, and produce very low level of PGE2. A relatively low dose of celecoxib (5-10 microM) induced G2/M arrest, followed by induction of apoptosis in the transformed but not in the normal cells. Down-regulation of cyclin B1 and up-regulation of p21 expressions independent of p53 might have cause this cell cycle block. Growth inhibition was related to COX-2 function with 90-95% reduction in PGE2 production. These findings may be of clinical importance, since low concentration of celecoxib can be achieved in human serum following standard anti-inflammatory (100-200 mg bid) regime.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426843     DOI: 10.1016/j.ejca.2005.11.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.

Authors:  D Altavilla; L Minutoli; F Polito; N Irrera; S Arena; C Magno; M Rinaldi; B P Burnett; F Squadrito; A Bitto
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Paris chinensis dioscin induces G2/M cell cycle arrest and apoptosis in human gastric cancer SGC-7901 cells.

Authors:  Lin-Lin Gao; Fu-Rong Li; Peng Jiao; Ming-Feng Yang; Xiao-Jun Zhou; Yan-Hong Si; Wen-Jian Jiang; Ting-Ting Zheng
Journal:  World J Gastroenterol       Date:  2011-10-21       Impact factor: 5.742

3.  Celecoxib pathways: pharmacokinetics and pharmacodynamics.

Authors:  Li Gong; Caroline F Thorn; Monica M Bertagnolli; Tilo Grosser; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

4.  Neurogenic transdifferentiation of human adipose-derived stem cells? A critical protocol reevaluation with special emphasis on cell proliferation and cell cycle alterations.

Authors:  Kai Michael Kompisch; Claudia Lange; Doris Steinemann; Britta Skawran; Brigitte Schlegelberger; Reinhard Müller; Udo Schumacher
Journal:  Histochem Cell Biol       Date:  2010-10-13       Impact factor: 4.304

5.  25-Hydroxycholesterol exerts both a cox-2-dependent transient proliferative effect and cox-2-independent cytotoxic effect on bovine endothelial cells in a time- and cell-type-dependent manner.

Authors:  Alyssa Cantarutti; Alyssa Terminesi; Cassandra Mendonca; Vicky Pkh Nguyen; Stephen H Chen; Katerina Pizzuto; Daniel J Dumont
Journal:  J Angiogenes Res       Date:  2010-11-11

6.  Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.

Authors:  Yun-Jeong Lim; Jong-Chul Rhee; Young-Mee Bae; Wan-Joo Chun
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

7.  Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.

Authors:  Bassel F El-Rayes; Mark M Zalupski; Stephanie G Manza; Barbara Rusin; Ann Marie Ferris; Ulka Vaishampayan; Lance K Heilbrun; Raghu Venkatramanamoorthy; Anthony F Shields; Philip A Philip
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

8.  Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest.

Authors:  Shui-er Zheng; Sang Xiong; Feng Lin; Guang-lei Qiao; Tao Feng; Zan Shen; Da-liu Min; Chun-ling Zhang; Yang Yao
Journal:  Acta Pharmacol Sin       Date:  2012-05-14       Impact factor: 6.150

9.  Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

Authors:  A Jimeno; A Chan; G Cusatis; X Zhang; J Wheelhouse; A Solomon; F Chan; M Zhao; S C Cosenza; M V Ramana Reddy; M A Rudek; P Kulesza; R C Donehower; E P Reddy; M Hidalgo
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

10.  Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.

Authors:  Khong Bee Kang; Congju Zhu; Sook Kwin Yong; Qiuhan Gao; Meng Cheong Wong
Journal:  Mol Cancer       Date:  2009-08-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.